AstraZeneca touts upbeat asthma data for key respiratory candidate

It's one step back, one step forward for AstraZeneca's ($AZN) key respiratory drug benralizumab. After acknowledging a midstage setback in COPD last month, AstraZeneca's big MedImmune division has come back with positive--though somewhat mixed--Phase IIb data underscoring the effectiveness of knocking down white blood cells in preventing asthma attacks. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.